Aleksandra Szczęsna

12.0k total citations · 7 hit papers
73 papers, 5.8k citations indexed

About

Aleksandra Szczęsna is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Aleksandra Szczęsna has authored 73 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Aleksandra Szczęsna's work include Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (34 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Aleksandra Szczęsna is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (34 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Aleksandra Szczęsna collaborates with scholars based in Poland, Germany and United Kingdom. Aleksandra Szczęsna's co-authors include Rodryg Ramlau, Joachim von Pawel, Jose R. Pereira, A Płużańska, E. Kaukel, U. Gatzemeier, Maciej Krzakowski, Tudor–Eliade Ciuleanu, Keunchil Park and Filippo de Marinis and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Aleksandra Szczęsna

70 papers receiving 5.6k citations

Hit Papers

Cetuximab plus chemotherapy in patients with advanced non... 2003 2026 2010 2018 2009 2010 2003 2007 2016 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
    2009 1.0k citations Robert Pirker, Aleksandra Szczęsna et al. profile →
  2. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    2010 917 citations Tudor–Eliade Ciuleanu, Aleksandra Szczęsna et al. The Lancet Oncology profile →
  3. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
    2003 763 citations Joachim von Pawel, K. Mattson et al. Journal of Clinical Oncology profile →
  4. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
    2007 706 citations U. Gatzemeier, Aleksandra Szczęsna et al. Journal of Clinical Oncology profile →
  5. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
    2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
  6. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    2018 336 citations Fabrice Barlési, Johan Vansteenkiste et al. The Lancet Oncology profile →
  7. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aleksandra Szczęsna Poland 23 4.4k 4.2k 1.2k 665 463 73 5.8k
Shunichi Sugawara Japan 36 4.2k 1.0× 3.5k 0.8× 1.1k 0.9× 548 0.8× 507 1.1× 209 5.4k
Nick Thatcher United Kingdom 34 4.0k 0.9× 3.9k 1.0× 1.5k 1.3× 810 1.2× 434 0.9× 117 5.7k
Piotr Serwatowski Germany 15 4.0k 0.9× 3.5k 0.9× 1.0k 0.9× 626 0.9× 415 0.9× 28 5.3k
Renato Martins United States 20 4.6k 1.0× 4.7k 1.1× 1.7k 1.4× 916 1.4× 396 0.9× 42 6.7k
Bilal Piperdi United States 35 3.9k 0.9× 2.8k 0.7× 821 0.7× 518 0.8× 529 1.1× 119 5.0k
Robert M. Jotte United States 31 5.6k 1.3× 4.0k 1.0× 1.4k 1.2× 744 1.1× 639 1.4× 111 6.9k
Mircea Dediu Romania 19 4.8k 1.1× 5.1k 1.2× 1.6k 1.3× 894 1.3× 267 0.6× 55 6.6k
Hidetoshi Hayashi Japan 36 3.7k 0.8× 2.8k 0.7× 1.4k 1.2× 705 1.1× 270 0.6× 248 5.2k
Naoyuki Nogami Japan 30 5.9k 1.3× 5.4k 1.3× 1.4k 1.2× 969 1.5× 311 0.7× 149 7.4k
Jin‐Ji Yang China 36 3.5k 0.8× 3.9k 0.9× 1.2k 1.0× 1.1k 1.6× 190 0.4× 146 4.9k

Countries citing papers authored by Aleksandra Szczęsna

Since Specialization
Citations

This map shows the geographic impact of Aleksandra Szczęsna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleksandra Szczęsna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleksandra Szczęsna more than expected).

Fields of papers citing papers by Aleksandra Szczęsna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleksandra Szczęsna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleksandra Szczęsna. The network helps show where Aleksandra Szczęsna may publish in the future.

Co-authorship network of co-authors of Aleksandra Szczęsna

This figure shows the co-authorship network connecting the top 25 collaborators of Aleksandra Szczęsna. A scholar is included among the top collaborators of Aleksandra Szczęsna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleksandra Szczęsna. Aleksandra Szczęsna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ramlau, Rodryg, Dariusz M. Kowalski, Aleksandra Szczęsna, et al.. (2025). Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC. Frontiers in Oncology. 15. 1544967–1544967.
2.
3.
Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology. 16(8). 1369–1378. 40 indexed citations
4.
Ciuleanu, Tudor–Eliade, Mark A. Socinski, Coleman K. Obasaju, et al.. (2017). OA23.02 Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study. Journal of Thoracic Oncology. 12(1). S334–S334. 1 indexed citations
5.
Reck, Martin, Alexander Luft, Aleksandra Szczęsna, et al.. (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 34(31). 3740–3748. 397 indexed citations breakdown →
6.
7.
Socha, Joanna, et al.. (2015). Accelerated hypofractionated thoracic radiotherapy in limited disease small cell lung cancer : comparison with the results of conventionally fractionated radiotherapy.. PubMed. 20(1). 146–57. 10 indexed citations
8.
Ciuleanu, Tudor–Eliade, Mark A. Socinski, Coleman K. Obasaju, et al.. (2015). Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study. Journal of Thoracic Oncology. 1 indexed citations
9.
Thatcher, Nick, Fred R. Hirsch, Alexander Luft, et al.. (2015). Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. The Lancet Oncology. 16(7). 763–774. 331 indexed citations breakdown →
10.
Quoix, Élisabeth, György Losonczy, Frédéric Forget, et al.. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. International Journal of Radiation Oncology*Biology*Physics. 90(5). S35–S35. 2 indexed citations
11.
Socha, Joanna, et al.. (2014). Hypofractionated Conformal Radiotherapy in Combination with Chemotherapy in Limited Disease Small Cell Lung Cancer Patients. Advances in respiratory medicine. 82(2). 105–115. 5 indexed citations
12.
Pirker, Robert, J. R. Pereira, Aleksandra Szczęsna, et al.. (2012). Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77(2). 376–382. 5 indexed citations
13.
Smit, Egbert F., Giorgio V. Scagliotti, Paul Lorigan, et al.. (2011). Biomarker analysis in a phase III study of pemetrexed–carboplatin versus etoposide–carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Annals of Oncology. 23(7). 1723–1729. 21 indexed citations
14.
Pirker, Robert, Aleksandra Szczęsna, Joachim von Pawel, et al.. (2009). Prognostic factors in advanced NSCLC: Experience from the FLEX trial. Journal of Clinical Oncology. 27(15_suppl). 8083–8083. 3 indexed citations
15.
Scagliotti, Giorgio V., George R. Blumenschein, Harry J.M. Groen, et al.. (2008). Sunitinib plus Erlotinib for the Treatment of Metastatic Non—Small-Cell Lung Cancer: A Novel VEGFR—EGFR Co-Inhibition Treatment Strategy. Clinical Lung Cancer. 9(5). 300–300. 1 indexed citations
16.
Gottfried, Maya, Rodryg Ramlau, Maciej Krzakowski, et al.. (2008). Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results. Journal of Thoracic Oncology. 3(2). 152–157. 23 indexed citations
17.
Scagliotti, Giorgio V., Aleksandra Szczęsna, Rodryg Ramlau, et al.. (2006). Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer. British Journal of Cancer. 94(10). 1375–1382. 25 indexed citations
18.
Digumarti, Raghunadharao, P. Koralewski, Piotr Serwatowski, et al.. (2005). P-560 A randomized phase II study of plvanex and docetaxel comparedto docetaxell monotherapy In patients with previously treated advanced NSCLC. Lung Cancer. 49. S265–S265. 3 indexed citations
19.
O’Brien, Mary, Aleksandra Szczęsna, Petr Zatloukal, et al.. (2004). Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study. Annals of Oncology. 15(6). 921–927. 17 indexed citations
20.
Manegold, C., Jürgen Debus, Giorgio V. Scagliotti, et al.. (2003). 827 A phase II randomized study comparing docetaxel/clsplatin induction therapy followed by thoracic radiotherapy with or without weekly docetaxel in unresectable stage IIIA–IIIB non-small cell lung cancer. European Journal of Cancer Supplements. 1(5). S248–S249. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Nick Thatcher Breakdown of academic impact, for papers by Piotr Serwatowski Breakdown of academic impact, for papers by Renato Martins Breakdown of academic impact, for papers by Bilal Piperdi Breakdown of academic impact, for papers by Robert M. Jotte Breakdown of academic impact, for papers by Mircea Dediu Breakdown of academic impact, for papers by Hidetoshi Hayashi Breakdown of academic impact, for papers by Naoyuki Nogami Breakdown of academic impact, for papers by Jin‐Ji Yang
Rankless by CCL
2026